Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced it would report its financial results for the first quarter of 2010 on Wednesday, April 28, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community scheduled for the following morning, Thursday, April 29, 2010 at 11:00 AM ET.

Neoprobe’s President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company’s results for the first quarter of 2010 during a conference call scheduled for 11:00 AM ET, Thursday, April 29, 2010. The conference call can be accessed as follows:
Conference Call Information
TO PARTICIPATE LIVE:     TO LISTEN TO A REPLAY:
Date:

Time:

 

Toll-free (U.S.) Dial in # :

International Dial in # :
  April 29, 2010

11:00 AM ET

 

877-407-8033

201-689-8033
   

Available until:

Toll-free (U.S.) Dial in # :

International Dial in # :

Replay Passcodes:

   Account #:

   Conference ID #:
  May 6, 2010

877-660-6853

201-612-7415

 

286

349832

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe ® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek ® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Copyright Business Wire 2010